Tuesday 11 July 2017
The British HIV Association (BHIVA) today celebrates the availability of pre-exposure prophylaxis (PrEP) for HIV on the NHS in Scotland, and its availability (from 17 July) on the NHS in Wales as part of a three-year trial.
BHIVA Chair, Professor Chloe Orkin, said: “All those responsible for gaining access to this life-changing drug on the NHS for people in Scotland and Wales should be proud of their tremendous achievement. It has not been an easy path.
“While celebrating this progress, we remain vigilant regarding the NHS England PrEP impact trial, which is currently due to begin in August. Recent reports indicating the positive impact of PrEP on HIV transmission in London highlight why the trial must remain a top priority for NHS England.”
In the most recent update on the PrEP impact trial, Public Health England and NHS England reported that NHS England ‘expects to be able to confirm the award of the final contract [for the supply of drugs to the trial] by 31 July 2017, meaning trial drugs could be available from early August, in readiness for the trial to begin once ethics approval is received and trial sites are prepared.’
For further information, please contact Curium Communications:
Jon Cope: 07867 508212
Founded in 1995, BHIVA is a well-established organisation which is committed to providing excellence in the care of those living with and affected by HIV. It acts as a national advisory body to professions and other organisations on all aspects of HIV care. BHIVA also provides a national platform for HIV care and contributes representatives for international, national and local committees dealing with HIV care. In addition, BHIVA works to promote undergraduate, postgraduate and continuing medical education within HIV care. www.bhiva.org @BritishHIVAssoc